Drug Trial Radar · NCT04504916
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
102
Actual
Start
Oct 7, 2020
Primary completion
Jun 12, 2023
Study completion Jun 12, 2023
Sponsor
- Lead sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.
Conditions
- Triple-negative Breast Cancer
- Non-squamous Non-small-cell Lung Cancer
- NSCLC
- Estrogen-receptor-positive Breast Cancer
- Progesterone-receptor-positive Breast Cancer
- Estrogen-receptor-negative Breast Cancer
- ER-negative Breast Cancer
- Progesterone-receptor Negative Breast Cancer
- PR-negative Breast Cancer
- HER2-negative Breast Cancer
- ER-positive Breast Cancer
- PR-positive Breast Cancer
- Platinum-resistant Ovarian Cancer
- Gastric Cancer
- Pancreatic Cancer
Interventions
Zilovertamab vedotinDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)Time frame: Up to ~18 months
Locations
14 sites in 2 countries. Site status is shown where the registry gives one.
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005)
Hollywood, Florida
AdventHealth Orlando ( Site 0003)
Orlando, Florida
Massachusetts General Hospital ( Site 0017)
Boston, Massachusetts
John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002)
Hackensack, New Jersey
Memorial Sloan Kettering Cancer Center ( Site 0007)
New York, New York
MD Anderson ( Site 0001)
Houston, Texas
The University of Texas Health Science Center at San Antonio ( Site 0004)
San Antonio, Texas
Swedish Medical Center ( Site 0008)
Seattle, Washington
Cross Cancer Institute ( Site 0012)
Edmonton, Alberta, Canada
BC Cancer Vancouver ( Site 0011)
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre ( Site 0006)
Toronto, Ontario, Canada
Centre intégré de cancérologie du CHUM ( Site 0016)
Montreal, Quebec, Canada
Jewish General Hospital ( Site 0013)
Montreal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.